Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Active, not recruiting · Phase 1 · NCT05753501
Conditions: Hematologic Cancer
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 14
- Sites paid
- 16
- Planned or actual enrollment
- 135
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-101 (drug)
- Dates
- Started 2023-06-09; completion 2031-03
- Results posted
- Not yet
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed f…
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.4M in research payments for this study in 2025 (133 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sudhir Manda, MD Hematology & Oncology · Tucson, AZ
- Catherine C. Coombs, M.D. Hematology & Oncology · Orange, CA
- Bita Fakhri, M.D., M.P.H Hematology · Palo Alto, CA
- John M. Burke, MD Hematology & Oncology · Aurora, CO
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Gottfried R. Von Keudell, MD, PHD Hematology & Oncology · Boston, MA
- Steven Allen Hematology & Oncology · Lake Success, NY
- Paul M. Barr, MD Hematology · Rochester, NY
- Joanna M. Rhodes, MD, MSCE Medical Oncology · New Hyde Park, NY
- Zulfa Omer, MD Hematology & Oncology · Cincinnati, OH
- Luke B. Fletcher, MD Hematology & Oncology · Eugene, OR
- John C. Byrd, M.D. Hematology · Pittsburgh, PA
- Elise A. Chong, MD Hematology & Oncology · Philadelphia, PA
- William G. Wierda, M.D., PHD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Strong Memorial Hospital, NY $434,275
- Board of Trustees of the Leland Stanford Junior University $411,665
- Uci Health-Orange, CA $116,581
- Ut MD Anderson Cancer Center $105,155
- University of Cincinnati $96,774
- Hospital of Univ of Pennsylvania, PA $86,922
- Rutgers the State University $84,984
- Northwestern University $44,634
- Beth Israel Deaconess Medical Center, MA $16,684
- $9,864
- The Feinstein Institute for Medical Research $4,238
- US Oncology Research LLC $1,800
- Stanford University School of Medicine $1,414
- Northwestern University Health Service Evanston $662
- Feinstein Institutes for Medical Research $600
- Willamette Valley Cancer Institute and Research Center - Eugene $600
- Arizona Oncology Associates PC-Hope $600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.